153 related articles for article (PubMed ID: 29980576)
21. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
Pontifex EK; Dissanayake K; Bursill D; Gill T
Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
[TBL] [Abstract][Full Text] [Related]
22. Influence of the timing of biological treatment initiation on Juvenile Idiopathic Arthritis long-term outcomes.
Oliveira Ramos F; Rodrigues AM; Melo AT; Aguiar F; Brites L; Azevedo S; Duarte AC; Gomes JAM; Furtado C; Mourão AF; Sequeira G; Cunha I; Figueira R; Santos MJ; Fonseca JE
Arthritis Res Ther; 2023 Sep; 25(1):177. PubMed ID: 37735435
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL.
Nicholls D; Barrett R; Button P; Truman M; Bird P; Roberts L; Tymms K; Littlejohn G; Griffiths H
Intern Med J; 2018 Oct; 48(10):1185-1192. PubMed ID: 29968400
[TBL] [Abstract][Full Text] [Related]
24. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
[TBL] [Abstract][Full Text] [Related]
25. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
Cho SK; Lee J; Han M; Bae SC; Sung YK
Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment.
Chen MH; Lee MH; Liao HT; Chen WS; Lai CC; Tsai CY
Clin Rheumatol; 2018 Feb; 37(2):429-438. PubMed ID: 29307092
[TBL] [Abstract][Full Text] [Related]
27. Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.
Rintelen B; Zwerina J; Herold M; Singer F; Hitzelhammer J; Halder W; Eichbauer-Sturm G; Puchner R; Stetter M; Leeb BF;
BMC Musculoskelet Disord; 2016 Aug; 17(1):358. PubMed ID: 27550175
[TBL] [Abstract][Full Text] [Related]
28. Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system.
Kosse LJ; Jessurun NT; Hebing RCF; Huiskes VJB; Spijkers KM; van den Bemt BJF; Nurmohamed MT
Rheumatology (Oxford); 2020 Jun; 59(6):1253-1261. PubMed ID: 31566226
[TBL] [Abstract][Full Text] [Related]
29. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
[TBL] [Abstract][Full Text] [Related]
31. Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries.
Lucasson F; Kiltz U; Kalyoncu U; Leung YY; Palominos P; Cañete JD; Scrivo R; Balanescu A; Dernis E; Meisalu S; Ryussen-Witrand A; Soubrier M; Aydin SZ; Eder L; Gaydukova I; Lubrano E; Richette P; Husni E; Coates LC; de Wit M; Smolen JS; Orbai AM; Gossec L
RMD Open; 2022 May; 8(1):. PubMed ID: 35523519
[TBL] [Abstract][Full Text] [Related]
32. Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study.
Cordtz R; Mellemkjær L; Glintborg B; Hetland ML; Madsen OR; Jensen Hansen IM; Dreyer L
Rheumatology (Oxford); 2016 Jun; 55(6):1017-22. PubMed ID: 26912584
[TBL] [Abstract][Full Text] [Related]
33. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
[TBL] [Abstract][Full Text] [Related]
34. Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement.
Solomon DH; Shadick NA; Weinblatt ME; Zak A; Frits M; Franklin JM
Arthritis Res Ther; 2017 Jun; 19(1):130. PubMed ID: 28610614
[TBL] [Abstract][Full Text] [Related]
35. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
36. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
38. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.
Hetland ML; Jensen DV; Krogh NS
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-141-6. PubMed ID: 25365104
[TBL] [Abstract][Full Text] [Related]
39. Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B.
King LK; Lee A; Anandacoomarasamy A
Intern Med J; 2012 May; 42(5):523-31. PubMed ID: 21790927
[TBL] [Abstract][Full Text] [Related]
40. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
Stevenson MD; Wailoo AJ; Tosh JC; Hernandez-Alava M; Gibson LA; Stevens JW; Archer RJ; Simpson EL; Hock ES; Young A; Scott DL
J Rheumatol; 2017 Jul; 44(7):973-980. PubMed ID: 28202743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]